Volume 45 Number 1
The significance of lifelong follow-up for the ostomate: the nurse’s perspective of ileostomy site adenocarcinomas
Kelly J Vickers
Keywords ileostomy, adenocarcinoma, stomal therapy nurse role
For referencing Vickers KJ. The significance of lifelong follow-up for the ostomate: the nurse’s perspective of ileostomy site adenocarcinomas. WCET® Journal. 2025;45(1):20-26.
DOI
10.33235/wcet.45.1.20-26
Submitted 9 July 2024
Accepted 15 December 2024
Abstract
The development of adenocarcinoma at an ileostomy site is an extremely uncommon and late complication that can occur for people living with a permanent ileostomy. Predominantly it is found in individuals who had their stoma surgery for ulcerative colitis, familial adenomatous polyposis or Crohn’s disease, at an average time of 27 years after the stoma was created. There have only been 70 reported cases in the literature worldwide, most of these in the last 20 years. The extended latent period for the adenocarcinoma to occur from time of stoma creation could help explain this increase in incidence. The exact cause of this malignancy is not clear but it has been suggested that factors such as chronic mechanical and chemical irritation from stoma appliances, disease predisposition, malignant transformation of adenomas, changes in bacterial flora and Ileitis/backwash ileitis, could contribute to their development.
Primary adenocarcinoma at an ileostomy has been reported in the literature by surgeons and medical practitioners. Despite this, there remains limited information on the care and management from key stakeholders such as stomal therapy nurses, when caring for a people living with a permanent ileostomy. This article provides a different understanding and description from the perspective of a stomal therapy nurse, describing two cases of primary adenocarcinoma at the ileostomy site.
Introduction
Primary adenocarcinoma at an ileostomy site is an extremely uncommon and late complication.1–6 Worldwide there have been only 70 cases reported in the literature up until 2020.2 The first reported case of a primary adenocarcinoma at an ileostomy site occurred in 1969 in a patient 19 years after a partial colectomy for ulcerative colitis (UC).5–8 The timeframe between stoma creation surgery and developing an adenocarcinoma lesion is varied with cases diagnosed as early as three years and as late as 51 years3 and the average time documented as 27 years.5–7
Primary adenocarcinoma at an ileostomy site is predominantly found in people with an initial diagnosis of UC and familial adenomatous polyposis (FAP),1 with some reports in patients with Crohn’s disease.2 Although occurrence in patients with FAP is rare. Permanent ileostomies are often created during surgeries to treat UC, FAP or Crohn’s disease. These conditions, in particular UC and FAP, can require total colectomies, proctocolectomies, ileal pouch, ileoanal anastomosis (restorative) and pan (total) proctocolectomies with permanent ileostomies.1,2 Temporary ileostomies can become permanent if the patient decides living with a stoma permanently is the preferred option, or they become medically unfit for further surgery.1
Pan proctocolectomy with permanent end ileostomy has been performed for individuals with UC or FAP since the 1950s.5 It involves removing the entire colon, rectum, anal canal and anal sphincter in one surgery with the formation of an end ileostomy, and is considered to be a curative treatment for FAP and UC.9 This was once considered the first line surgical treatment for UC and FAP patients, but today restorative proctocolectomy surgery is considered standard procedure avoiding a permanent ileostomy for the patient. 3,10
Stoma malignancies are not a complication that stomal therapy nurses (STNs) often encounter. Stomal therapy text books will only dedicate a paragraph or up to half a page to the topic, if at all, as it is so uncommon, therefore STN knowledge is lacking in this area. Experienced STNs may have limited exposure throughout their vast careers. This paper provides two case studies with insight into the identification and management of this condition.
Patient A
Case Presentation (Background)
A 54-year-old gentleman with a previous history of total proctocolectomy and formation of an end ileostomy in 2012 for FAP (also reported by Jacob et al7). Past medical history of depression, gastric oesopahgeal reflux disease (GORD), post-traumatic stress disorder (PTSD) and a BMI of 35, obese.
Patient A was lost to follow up due to non-adherence with health care and poor health literacy. He presented to the Emergency Department in January 2022 with a large painful and partially reducible parastomal hernia (PSH), peristomal skin damage and a hyper nodular stoma. An urgent referral to the colorectal team was completed followed by a review by the colorectal consultant and STN in the outpatient department. The patient reported no previous contact with an STN for at least three years.
On examination by the STN a large PSH was evident. On removing the stoma appliance, a large polypoid lesion was noted on the stoma mucosa, becoming the more concerning feature (Photos 1 & 2). Patient A reported the parastomal hernia had been increasing in size for years, and he experienced discomfort and multiple appliance leakages daily. He had started using Coloplast Mio Concave® drainable bag to improve adherence around the large PSH, as this appliance is designed to fit around bulges, hernias, and curves with its star shaped base. However, the opening of the bag was not being cut large enough by Patient A for the both the stoma and polypoid lesion resulting in device failure and persistent friction and irritation at appliance opening. Additionally, the patient cut an opening into the hernia support belt that he was using to accommodate the bag and not surprisingly, found that this worsened.
Photo 1 and 2. Anterior & Lateral view of polypoid lesion & PSH.
Management and Outcomes
Patient A had an urgent elective open parastomal hernia repair and refashioning of stoma. Mesh was not inserted due to unknown pathology of the polypoid lesion. Pathology of the large polypoid lesion that was excised returned as villous tumor with transformation into adenocarcinoma, with superficial focal invasion. Postoperatively, the stoma was irregular in shape and oedematous from being handled during the surgery, which is expected after stoma creation and slowly decreases in the first 4-6 weeks. A parastomal outwards protrusion was still evident and a lateral sutured wound for excess skin extending outwards at 9 o’clock, which further caused the parastomal area to be uneven and undulating (Photos 3 & 4).
Photo 3. Anterior view of parastomal topography post operative.
Photo 4. Lateral view of parastomal topography post operative
Photos 1–4 © 2023 Royal Australasian College of Surgeons.
Reprinted with permission from John Wiley & Sons Inc. Jacob M, Ponniah K,
Ramanathan B, Eteuati J. Primary adenocarcinoma arising from an ileostomy site:
a late complication of end ileostomies. ANZ Journal of Surgery.
He developed cellulitis to the peristomal skin requiring intravenous antibiotic treatment with Ceftriaxone during the recovery period and was discharged four days after his surgery with oral Augmentin Duo antibiotic coverage. On discharge, he was using the Welland Aurum® Profile drainable bag. The base of this product is designed to fit around curves, creases, and complex body contours which the patient had acquired post-surgery. It was also felt that the medical-grade Manuka honey infused base could assist with healing and decreasing the inflammation of the peristomal skin cellulitis (Photo 5 & 6).
Photo 5. Peristomal cellulitis. Photo 6. Parastomal area with appliance in place.
Post discharge in the community, the patient was changing his bag every two days with no leakages. Stoma care post discharge was complicated by developing a large pseudoverrucous lesion with moist hyperkeratotic tissue below the stoma, causing extreme pain and considerable bleeding (Photo 7). Visible erythema was managed with an extended course of oral antibiotics. The STN focused education on cutting the base to the correct size for his stoma, introducing a Welland Hyperseal® to manage the peristomal skin complication and correct use of support belt for parastomal hernia prevention.
Photo 7. Pseudoverrucous lesion with moist hyperkeratotic tissue.
Photo 8. Ostomy equipment Patient A was using in the community.
Patient B
Case Presentation (Background)
A 52-year-old woman with history of Crohn’s disease and a total colectomy with formation of end ileostomy in 1985 when she was 14 years old. She had a complex medical history of pulmonary sarcoidosis, an inflammatory disease in which cells of the immune system cluster together to form tiny noncancerous masses, usually in the lungs and nearby lymph nodes.11 She was immunosuppressed from methotrexate treatment for her sarcoidosis, lung function tests demonstrated a severe obstructive ventilatory defect, mild obstructive sleep apneoa (OSA), prednisolone related Type 2 diabetes, depression, and a BMI of 30, obese. This patient reported no follow up by a gastroenterologist, colorectal surgeon or STN following her total colectomy 38 years prior. The patient displayed poor health literacy.
Patient B presented to the Emergency Department in November 2023 with an 18-month history of a progressive polypoid growth to her ileostomy causing pain, bleeding, peristomal skin complications and increased appliance leakages, leading to her to apply Super Glue® to her appliance base as the best management option to counteract leakage. At the time patient B was using a Coloplast Mio® convex drainable appliance, with no additional seals or belt.
On examination a polypoid lesion was to the right side of the stoma mucosa at 9 o’clock and almost twice the size, dwarfing her stoma. Her peristomal skin was significantly eroded from the frequent appliance leakages, and damaged from the use of Super Glue®.
Pathology of punch biopsies taken in the Emergency Department returned as invasive low-grade mucin producing adenocarcinoma. Patient B underwent further preoperative staging with CT, PET and ileoscopy.
Photo 9. Polypoid lesion at 9 o’clock and eroded peristomal skin.
Management and outcomes
The patient had an urgent elective local resection and revision of the ileostomy. Pathology of the lesion confirmed prior biopsies of low-grade mucinous adenocarcinoma infiltrated into perintestinal fat. Postoperatively, her stoma was red and protruding with lateral sutured wounds for excess skin extending outwards at 3 and 9 o’clock, which exudated low to moderate amounts of serous fluid (photo 10).
Photo 10. Post operative topography of parastomal area with lateral sutured wounds.
Photo 11. Ostomy equipment Patient B was using in the community.
A large Welland® seal was applied to the peristomal skin and lateral wounds to assist in absorbing the wound exudate, with a Dansac Novalife® soft convex drainable bag. Her recovery was complicated with a post operative ileus, but she was eventually discharged seven days after her surgery using a Salts® modulable seal, Dansac Novalife® soft convex drainable bag and Coloplast Brava® elastic tape, and re-educated on using a support belt for parastomal hernia prevention.
Post discharge in the community, Patient B was self-caring for her stoma and changing her bag every 4–5 days with no leakages. Unfortunately, since being discharged, her stoma care has been further complicated by pyoderma gangrenosum to the peristomal skin and episodes of bowel obstructions from a parastomal hernia requiring inpatient admissions.
Both Patient A and Patient B now receive regular reviews in the stomal therapy outpatient clinic and have an STN service that they can contact at any time as needed.
Discussion
Both case studies presented with a known background diagnosis of either FAP or Crohn’s disease, both of which are known and identified in the literature as a precursor to developing primary adenocarcinoma at an ileostomy site. As a known late complication, with an average time of development 27 years from stoma creation5–7, these patients had their primary adenocarcinomas diagnosed at 10 and 38 years, respectively, after their stoma creation. Exhibiting symptoms which include a growing mass at stoma site, painful or uncomfortable lesions/polyps, bleeding, skin irritations and difficulty with appliance adhesion. 2,3,4,12 Other characteristics can include papules, wound on the peristomal area, bowel obstruction and stenosis of the stoma. 3,4
The etiology of primary adenocarcinoma at an ileostomy site is not definitive or clear1 and there are several possible hypotheses for its cause.
Chronic mechanical and chemical irritation to the mucocutaneous junction
Repetitive peristomal trauma from incorrectly fitted stoma appliances and exposure to chemicals used in the adhesives of these may lead to metaplasia and dysplasia of the ileal mucosa. 1,3,5,10,12 This irritation usually occurs at the mucocutaneous junction and then invades into the surrounding skin and tissue.5 Metaplasia occurs when the normal cells are turned into other less recognisable cells in response to a chronic external stress or injury, and is reversible or benign.13 While dysplasia is an abnormal development of tissues or organs altering cell growth.13 This metaplasia and dysplasia can eventually lead to malignant changes such as adenocarcinoma.3 Both patients in this case series had been using ill-fitting stoma bags for many years prior to their initial review with the STN.
The hydrocolloid adhesives in stoma appliances commonly contain pectin, carboxymethyl cellulose (CMC) and polyisobutylene (PIB), with some ostomy manufacturers including tackifiers (to increase tack and stickiness), pH buffers and skin friendly additives such as aloe vera, manuka honey and ceramide. Table 1 describes the base ingredients found in most hydrocolloid stoma adhesives.
Table 1. Base ingredients in hydrocolloid adhesives. Dansac Glossary,. https://www.dansac.com.au/en-au/glossary
The literature evidences stoma appliances and accessories can cause or trigger peristomal irritant and allergic dermatitis.15 Stoma appliances including adhesive removers, barrier wipes and flanges can contain ingredients such as ethanol, ethyl alcohol, butyl alcohol, hexamethyldisiloxane, acrylate terpolymer and stearic acid.15 Avallone et al16 even describe an uncommon cause of PIB urolithiasis believed to be from the use of the patient’s ostomy appliance. The long-term exposure to the materials in stoma appliances and accessories on ileal mucosa may not be clear, potentially becoming carcinogenic.19 There is a paucity of information concerning this that requires further research.
Disease predisposition and malignant transformation of adenomas
Permanent ileostomies are often created during surgeries to treat UC, FAP and Crohn’s disease. FAP patients carry the adenomatous polyposis gene and are susceptible to bowel adenomas on their ileostomy leading to carcinoma formation through genetic mutations of K-Ras, β-catenin and p53.1-3 UC and Crohn’s Disease are also both known to have an associated increased risk of bowel cancer17 and the possible presence of benign adenomas risk adenocarcinoma development.
Changes in bacterial flora
Changes in bacterial flora have been linked with cancer occurrence.1,3 Changes in the flora of the faecal output at the ileostomy and surrounding peristomal skin can start to resemble that of colonic flora, which thrive in a different pH, oxygen level and nutrient environment, promoting colonic metaplasia and influencing cancer development.12,18 Additionally, it has been suggested that the constant exposure and irritation of the faecal output on the mucocutaneous junction (MCJ) and peristomal skin can cause metaplasia like that in Barrett’s oesophagous.4, 19
Ileitis or backwash ileitis
Ileitis is the inflammation of the ileum, seen in patients with Crohn’s disease,13 while backwash ileitis is the inflammation of the terminal ileum usually only in patients with UC.20 UC disease usually only involves the colon and rectum, not the ileum, but it has been suggested that inflammation can cause a malfunction at the ileocaecal valve allowing reflux of colonic material into the ileum, leading to terminal ileitis.20 There is a reported association between ileitis or backwash ileitis and mucosal dysplasia leading to the formation of cancer.1,2,3,5 According to Quah et al, “Adenocarcinomas are known to develop in the terminal ileum of patients with ulcerative colitis who have chronic ‘backwash’ ileitis.”12
The core principle that underlies all these hypotheses is there is a source of irritation causing inflammation, leading to metaplasia and dysplasia, and finally resulting in cancer formation.
Since 1969, when the first case of primary adenocarcinoma at an ileostomy site was reported, there have been 70 reported cases in the literature worldwide, most of these in the last 20 years. Table 2 outlines the increase of reported adenocarcinomas at an ileostomy site in the literature.
Table 2. Reported cases of adenocarcinoma at ileostomy site in the literature
The increase in reported cases over recent years would suggest a rise in the incidence of adenocarcinoma at the ileostomy site.3 This rise in incidence could be related to the long length of time it takes for the adenocarcinoma to occur from time of stoma creation.3,6 The average time between stoma creation surgery and developing an adenocarcinoma lesion has been documented as 27 years.5–7 Professor Brooke in 1952, first introduced the technique of everting the ileostomy which transformed treatment for UC in particular and was known as the Brooke (end) Ileostomy.3,6,12 It could therefore be logical to suggest that with an aging population of patients who had the Brooke (end) Ileostomy many years ago, they are reaching the time period where ileostomy adenocarcinoma would be occuring.3 Today restorative proctocolectomy surgery is instead considered standard procedure avoiding a permanent ileostomy for the patient.3,10. This may change the incidence of ileostomy adenocarcinoma going forward. As this is such an uncommon complication, it is possible that it has been under diagnosed and/or under reported with medical practitioners now being better at identifying and reporting these cases in academic journals.
The STN can play an important role in the identification and management of a primary adenocarcinoma at a stoma site. The STN is often the first medical professional ostomates present to with any changes to their stoma or ill-fitting and leaking appliances.24 It is recommended that longstanding ostomates with an ileostomy for more than 9–15 years, are reviewed annually by the STN to check for any malignant changes and allow early detection.1,3,4,7,12 Best practice and evidenced-based models already support that people living with a stoma should be reviewed by a qualified STN at least every 1–2 years and ongoing for the life of the stoma to ensure that they are using the most appropriate appliances and practices.25 This has long been considered the gold standard of practice by STNs. STNs need to be aware of this late complication and observant to any abnormal growths, lesions or non-healing wounds that do not respond to usual treatments.1,19 These should be referred for biopsy and treatment options may include excision of the affected area and refashioning or relocation of stoma.26 While managing the lesion within the patient’s stoma care, the STN can initiate the use of highly absorbent seals and barriers for the mucin created by the nodules, revise any templates or precut appliances to accommodate the size of the nodules and educate the patient on how to protect any peristomal skin that has become exposed.9
The role of the STN is often complex, involving early detection and preventative actions to stop adverse events and an ability to identify and respond to patient changes or deterioration.9 As a clinical specialist, the STN is an expert practitioner in this clinical field, delivering necessary knowledge, research-based practice, excellence in clinical practice and patient-centered care to ostomy patients.4 The STN should be mindful with their provision of information and education to improve overall health literacy for the patient and significant others. Health literacy refers to “the skills, knowledge, motivation and capacity of a person to gain access to, understand, appraise and apply information to make effective decisions about health and health care, and take appropriate action”. 27
The health literacy of both the patients in this case series, impeded them from contacting a STN for assistance with stoma issues. Both patients lacked the knowledge and motivation to seek assistance earlier. One patient delaying their surgery by two years a result of keeping a Category 1 surgical booking form at home for this period without contacting the hospital, and another applying Super Glue® to the stoma site to prevent leakages. These decisions may have delayed access to appropriate and timely healthcare, and the assessment, identification, diagnosis, and treatment of their adenocarcinoma. Low health literacy can be a common yet under reported issue within stomal therapy. Approximately 60% of Australian adults have a low level of health literacy required for daily life.27 The STN role was key in optimising care once the patients presented at the hospital, providing simple and clear visual and written stoma education to these patients. They were further supported in their health care management by close outpatient stoma care with regular appointments, surveillance, and individualised easy-to-understand education on how and when to seek STN assistance.
Conclusion
The substantially late onset of a primary adenocarcinoma at an ileostomy highlights the incredibly significant role the stomal therapy nurse plays in the lifelong care of an ostomate. Primary adenocarcinoma at a permanent ileostomy is a rare complication, however the number of reported cases in the last 20 years have almost doubled. This reported case series describes two patients who presented to the same hospital with this complication less than two years apart. Both had not been reviewed by an STN for a substantial amount of time and were not aware that the changes to their stoma were abnormal.
The exact cause of primary adenocarcinoma is not conclusive but it has been suggested that factors such as chronic mechanical and chemical irritation, disease predisposition, malignant transformation of adenomas, changes in bacterial flora and Ileitis/backwash ileitis, could contribute to their development. Medical practitioners and STNs should be vigilant when caring for persons with a longstanding permanent ileostomy. Careful examination of the stoma should be performed at each review. An annual review with an STN to detect any growths or abnormalities early is recommended, for as long as the ostomate lives with their stoma.
Limitations
As this clinical case study is a retrospective chart review, education specific to stoma care was difficult to ascertain. However, evidence of management of stoma appliances and support belt is noted in the text.
Acknowledgments
Thanks to Dr Julie Tucker, Clinical Research Nurse Consultant, Division Surgical Specialties and Anaesthetics, Northern Adelaide Local Health Network for proofreading and editing this article.
Conflicts of Interest
The author declares no conflict of interest.
Ethics
Central Adelaide Local Health Network Human Research Ethics Committee Ref 19710.
Funding
The author received no funding for this article.
造口患者终身随访的重要性:回肠造口部位腺癌的护士视角
Kelly J Vickers
DOI: 10.33235/wcet.45.1.20-26
摘要
永久性回肠造口患者可能发生一种极为罕见且迟发的并发症Å\Å\回肠造口部位腺癌。该病主要见于因溃疡性结肠炎、家族性腺瘤性息肉病或克罗恩病接受造口手术的患者,发病时间平均为术后27年。全球文献仅报告70例,其中多数病例出现在近20年内。腺癌自造口建立至发病之间的较长潜伏期,可能是发生率上升的原因之一。该恶性肿瘤的确切病因尚未明确,潜在相关因素可能包括造口装置的慢性机械性及化学性刺激、原发疾病的易感性、腺瘤的恶性转化、菌群改变以及回肠炎/倒灌性回肠炎。
现有文献中关于回肠造口原发性腺癌的报告多来自外科医生和内科医生。然而,目前造口治疗护士等关键护理人员在永久性回肠造口患者中的护理和管理信息仍十分有限。本文从造口治疗护士的视角出发,通过两例回肠造口部位原发性腺癌病例提供不同的理解与阐述。
引言
回肠造口部位原发性腺癌是一种极其罕见且迟发的并发症。1–6截至2020年,全球文献仅报告70例。2首例病例报告于1969年,该患者因溃疡性结肠炎(UC)行部分结肠切除术后19年发病。5–8从造口术到腺癌病变发生的时间跨度差异显著,最短为术后3年,最长达51年3,文献记载平均时间为27年。5–7
该疾病多见于初始诊断为UC和家族性腺瘤性息肉病(FAP)1的患者,少数报告见于克罗恩病患者,2但FAP患者中的发生率较低。通常因UC、FAP或克罗恩病治疗手术进行永久性回肠造口,特别是UC和FAP患者可能需接受结肠完全切除术、直肠结肠切除术、回肠袋、回肠肛管吻合术(重建性)以及全直肠结肠切除术(伴永久性回肠造口)。1,2若患者选择维持造口状态或因健康原因无法再行手术,临时性造口亦可能转为永久性造口。1
自20世纪50年代起,全直肠结肠切除术联合永久性末端回肠造口术应用于UC或FAP患者。5该术式通过一次性切除整个结肠、直肠、肛管及肛门括约肌,同时建立末端回肠造口,被视为FAP和UC的根治性治疗方案。9虽然该术式曾被视为UC和FAP的一线治疗方案,但现今重建性直肠结肠切除术已成为标准手术,可避免患者接受永久性造口。3,10
造口恶性肿瘤并非造口治疗护士(STN)常见并发症。由于该病症极为罕见,造口治疗专业教材往往仅以一段或半页篇幅简要提及,导致STN在此领域的知识储备不足。即使经验丰富的STN在其整个职业生涯中也鲜少接触此类病例。本文通过两项病例研究,深入探讨该病的识别与管理策略。
患者A
病例介绍(背景)
一例54岁男性患者因FAP于2012年接受全直肠结肠切除术及末端回肠造口术(Jacob等人亦有报告7)。既往病史包括抑郁、胃食管反流病(GORD)、创伤后应激障碍(PTSD),BMI为35(肥胖)。
患者A因医疗依从性差及健康素养不足而失访。该患者于2022年1月因大型疼痛性、部分可复性造口旁疝(PSH)伴造口周围皮肤损伤及造口结节样増生就诊急诊科。经紧急转诊至结直肠团队后,由结直肠专科顾问及STN进行门诊评估。患者自述已至少三年未接受过STN随访。
STN查体观察到一处大型PSH。移除造口装置后,观察到造口黏膜上存在一处大型息肉样病变,成为更值得关注的临床特征(照片1、2)。患者A自述造口旁疝体积逐年増大,日常出现不适感并频繁发生造口装置渗漏。患者已开始使用Coloplast Mio Concave®可引流型造口袋,以改善因大型造口旁疝导致的贴合问题。该产品采用星形底盘设计,适用于膨出、疝体及曲度部位。然而,患者A在剪裁造口袋开口时未能覆盖造口及息肉样病变的全部区域,导致装置失效,并在开口处造成持续摩擦与刺激。此外,患者为适配造口袋,在所使用的疝托带上自行裁剪开口,此举意料之中加重了病情。
照片1和2.息肉样病变和PSH的前视图和侧视图。
管理与结局
患者A接受了急诊择期开放性造口旁疝修补术及造口重建术。由于息肉样病变病理性质未明,未置入网片。切除的大型息肉样病变病理结果为绒毛状瘤伴腺癌变,并有浅表局灶浸润。术后造口因术中操作呈现形态不规则伴水肿,属于造口重建术后的预期表现,通常于4-6周内逐渐缓解。术区仍可见明显的造口旁外凸,同时于9点钟方向存在一处因多余皮肤延展所致的侧向缝合伤口,进一步致使造口周围区域呈现不规则波浪状(照片3、4)。
照片3.术后造口旁区域形态前视图。
照片4.术后造口旁区域形态侧视图。
照片1-4 ˝ 2023澳大利亚皇家外科医师学院。
经John Wiley & Sons Inc.授权转载,源自Jacob M, Ponniah K, Ramanathan B, Eteuati J. Primary adenocarcinoma arising from an ileostomy site: a late complication of end ileostomies. ANZ Journal of Surgery.
恢复期间,患者发生造口周围皮肤蜂窝织炎,予以头孢曲松静脉抗感染治疗。术后第4天出院,继续口服安美汀复方抗生素治疗。出院时使用Welland Aurum® Profile引流型造口袋,该产品底盘设计可贴合患者术后形成的曲线、皱褶及复杂的体表轮廓。同时,浸润医用级麦卢卡蜂蜜的底盘有助于促进伤口愈合并减轻造口周围皮肤蜂窝织炎的炎症反应(照片5、6)。
照片5.造口周围蜂窝织炎。 照片6.佩戴造口装置的造口旁区域。
出院后居家随访期间,该患者每两日更换一次造口袋且未发生渗漏。在后续护理过程中,造口下方出现一处大型假疣状病变,伴湿润性角化过度组织,导致剧烈疼痛并出现明显出血
(照片7)。可见红斑通过延长口服抗生素疗程得以控制。STN重点指导了患者关于造口底盘裁剪尺寸的规范化操作、采用Welland Hyperseal®产品处理造口周围皮肤并发症,以及正确使用疝托带预防造口旁疝。
照片7.伴湿性角化过度组织的假性疣状病变。
照片8.患者A在社区使用的造口装置。
患者B
病例介绍(背景)
一例52岁女性患者,因克罗恩病于1985年14岁时接受结肠完全切除术及末端回肠造口术。该患者的复杂病史包括肺结节病(一种免疫细胞聚集形成非癌性微小团块的炎症性疾病,通常累及肺部及邻近淋巴结),11此外,该患者还存在因肉状瘤病接受甲氨蝶呤治疗导致的免疫抑制状态、肺功能测定显示重度阻塞性通气障碍、轻度阻塞性睡眠呼吸暂停(OSA)、泼尼松龙相关2型糖尿病、抑郁,且BMI为30
(肥胖)。患者自述全结肠切除术后38年间未接受消化内科医师、结直肠外科医生或STN随访,且健康素养低下。
2023年11月,患者因回肠造口处持续18个月的进行性息肉样病变就诊急诊科,该病变已引发疼痛、出血、造口周围皮肤并发症,并导致造口装置渗漏加重,迫使患者尝试使用Super Glue®固定底盘以应对渗漏问题。就诊时,患者B使用Coloplast Mio®凸面引流型造口袋,未配合使用密封件或支撑带。
查体观察到造口黏膜右侧9点钟方向存在一处息肉样病变,其体积几乎为造口的两倍,明显遮蔽了造口。造口袋频繁渗漏导致其造口周围皮肤严重糜烂,Super Glue®的使用加剧了皮肤损伤。
急诊科行穿刺活检病理结果为低级别黏液分泌型浸润性腺癌。患者B随后接受CT、PET及回肠镜检查以完成术前分期评估。
照片9.9点钟方向息肉样病变及糜烂的造口周围皮肤。
管理与结局
该患者接受急诊择期局部切除术联合回肠造口修复术。病变病理证实为先前活检诊断的已浸润肠周脂肪的低级别黏液性腺癌。术后造口呈红色外翻状态,3点及9点钟方向可见因多余皮肤切除而形成的侧向缝合伤口,伤口渗出少量至中量浆液(照片10)。
照片10.术后造口旁区域形态及侧向缝合伤口。
照片11.患者B在社区使用的造口装置。
造口周围皮肤及侧向伤口处使用Welland®大号密封垫吸收伤口渗液,并搭配Dansac Novalife®软质凸面引流型造口袋。术后恢复期间出现肠麻痹,最终于术后7天出院。出院时使用Salts®可调节密封垫、Dansac Novalife®软质凸面引流型造口袋及Coloplast Brava®弹性胶带,并再次接受支撑带使用指导以预防造口旁疝。
出院后居家随访期间,患者B能自主进行造口护理,每4-5天更换造口袋,未出现渗漏。然而,该患者出院后相继出现造口周围皮肤坏疽性脓皮病及造口旁疝所致肠梗阻反复发作,需多次住院治疗。
目前患者A与患者B均已纳入造口治疗门诊定期随访体系,并可根据需要随时联系STN获取专业支持。
讨论
这两项病例研究的已知背景诊断为FAP或克罗恩病,这两种疾病已在文献中确认为回肠造口部位原发性腺癌的前驱病变。作为一种已知的迟发性并发症,该疾病平均发生于造口术后
27年5–7,本文分析的两例分别于造口术后10年与38年确诊。临床症状包括造口部位肿块増大、疼痛性或不适性病变/息肉、出血、皮肤刺激及造口装置黏附困难。2,3,4,12其他特征还包括丘疹、造口周围区域溃疡、肠梗阻及造口狭窄。3,4
回肠造口部位原发性腺癌的病因学尚未明确1,目前存在多种可能的致病假设。
皮肤黏膜交界处的慢性机械性与化学性刺激
造口装置适配不当造成的造口周围反复创伤,以及造口粘合剂中的化学物质的持续接触,可能诱导回肠黏膜化生和异型増生。1,3,5,10,12此类刺激通常始于皮肤黏膜交界处,继而侵袭周围皮肤及组织。5化生是指正常细胞在长期外部刺激或损伤的作用下转化为其他不易识别的细胞类型,此过程具有可逆性或良性特征;13而异型増生则是组织或器官的异常发育导致细胞生长改变。13此类化生与异型増生最终可能恶变为腺癌等恶性肿瘤。3本病例系列中的两例患者在STN初次评估前,均已长期使用不合适的造口袋。
造口装置中的水胶体粘合剂成分通常含有果胶、羧甲基纤维素(CMC)和聚异丁烯
(PIB),部分制造商还会添加増粘剂(増强黏性)、pH缓冲剂、芦荟、麦卢卡蜂蜜、神经酰胺等皮肤友好成分。大多数水胶体造口粘合剂的基础成分见表1。
表1.水胶体粘合剂基础成分。Dansac术语库;https://www.dansac.com.au/en-au/glossary
已有文献证实造口装置及辅助用品可能导致或引发造口周围刺激性和过敏性皮炎。15造口装置(包括黏胶去除剂、底盘巾及法兰)可能含有乙醇、乙基酒精、丁醇、六甲基二硅氧烷、丙烯酸酯三元共聚物和硬脂酸等成分。15Avallone等人16甚至报告过一例罕见的PIB尿石症病例,推测与患者使用的造口装置有关。回肠黏膜长期暴露于造口装置和辅助用品的影响尚未明确,但可能存在致癌风险。19目前相关资料和数据匮乏,需进一步探索和研究。
疾病易感性和腺瘤恶性转化
通常因UC、FAP和克罗恩病治疗手术需要建立永久性回肠造口,FAP患者携带腺瘤性息肉病基因,其回肠造口部位易发生肠道腺瘤,并通过K-Ras、É¿-连环蛋白和p53基因突变导致癌变。1-3已知UC和克罗恩病均会増加腺癌发生风险17,且可能存在的良性腺瘤有发展为腺癌的潜在风险。
菌群变化
菌群变化与癌症发生存在关联。1,3回肠造口排泄物及周围皮肤的菌群可逐渐转变为类似结肠菌群的组成,而结肠菌群适应于不同的pH值、氧含量和营养环境,从而可能促进结肠化生并影响肿瘤发展。12,18此外,排泄物对皮肤黏膜交界处(MCJ)及造口周围皮肤的持续暴露和刺激可能引发类似巴氏食管的化生改变。4, 19
回肠炎或倒灌性回肠炎
回肠炎指回肠的炎症反应,常见于克罗恩病患者;13而倒灌性回肠炎表现为末端回肠炎症,通常仅发生于UC患者。20UC病变通常仅累及结肠和直肠,但研究提示炎症可能导致回盲瓣功能障碍,使结肠内容物反流至回肠,进而引发末端回肠炎。20现有报告显示回肠炎或倒灌性回肠炎与黏膜异型増生存在关联,最终可能导致癌变。1,2,3,5如Quah等人所述:“已知溃疡性结肠炎伴慢性‘倒灌性’回肠炎患者的末端回肠可能发生腺癌”。12
这些假设的核心机制在于,刺激源引发炎症反应,导致化生和异型増生,最终可能发展为癌症。
自1969年首例回肠造口部位原发性腺癌报告以来,全球文献共记载70例,其中近20年病例占比最高。文献中关于回肠造口部位腺癌报告的増长趋势见表2。
表2.文献中报告的回肠造口部位腺癌病例
近年来病例报告数量的増加表明回肠造口部位腺癌发生率可能呈上升趋势。3这种増长可能与造口术至腺癌发生的长潜伏期相关,3,6文献记载造口术到腺癌病灶形成的平均间隔为27年。5–7 Brooke教授于1952年首创回肠外翻造口技术,显著改善了UC的治疗方式,因此也称为Brooke式(末端)回肠造口术。3,6,12由此可合理推测,多年前接受Brooke末端回肠造口术的患者人群正逐步进入回肠造口腺癌的高发年龄段。3当前,重建性直肠结肠切除术已成为主流手术方式,可避免患者永久留置造口,3,10可能会对未来回肠造口腺癌的发病趋势产生影响。由于该并发症极为罕见,既往可能存在诊断不足和/或报告不足的情况,而现今医疗人员对其识别和报告能力已显著提高。
STN在造口部位原发性腺癌的识别与管理中发挥着关键作用。STN通常是造口患者出现造口异常变化或装置渗漏等问题时最先接触的医疗专业人员,24建议对造口时间超过9-15年的长期回肠造口患者接受年度随访,以筛查恶性病变并实现早期发现。1,3,4,7,12最佳实践与循证模式均支持造口患者应每1-2年接受一次具有资质认证的STN评估,并在整个造口存续期间持续随访,以确保使用最合适的装置及护理方案,25此随访机制一直作为STN实践的金标准。STN需充分认识该迟发并发症,并对任何异常増生、病变或对常规治疗无反应的难愈性伤口保持高度警觉。1,19如发生上述情况,应及时转诊进行活检,治疗方案可包括病灶切除以及造口修整或移位。26在患者造口护理过程中,STN可使用高吸收性密封垫和底盘处理结节产生的黏液、调整造口模板或预裁式造口装置以适配结节尺寸,并指导患者保护已暴露的造口周围皮肤。9
STN的职责具有多重性,包括通过早期发现与预防干预以避免不良事件,并及时识别和应对患者病情变化或恶化。9作为临床专家,STN需在其专业领域输出必要的知识、循证实践、卓越的临床技能及以患者为中心的护理。4STN应注重通过相关健康信息和宣教提升患者及其护理者的整体健康素养。健康素养系指“个体获取、理解、评估并应用健康信息做出健康和医疗保健的有效决策及采取适当行动所需的技能、知识、动机和能力”。27
本病例系列中两例患者的健康素养不足,未能及时寻求STN的专业帮助。两例患者均缺乏尽早求医的知识与动机:其中一例将1类手术预约单搁置家中长达两年,始终未联系医院安排手术;另一例则尝试使用Super Glue®粘合造口部位以防止渗漏。这些决定可能延误其获得适当且及时的医疗干预,从而推迟了对腺癌的评估、识别、诊断和治疗。健康素养低下是造口治疗领域中常见但未充分报告的问题。约60%的澳大利亚成人缺乏日常生活所需的健康素养水平。27当患者前往医院就诊时,STN作为关键角色及时介入,为其提供简明直观的图文教育。在后续的健康管理中,患者还通过密切的门诊造口护理获得持续支持,包括定期随访、病情监测,以及关于何时以及如何寻求STN帮助的个体化、通俗易懂的健康教育。
结论
回肠造口部位原发性腺癌具有明显迟发性,突显了造口治疗护士在患者造口终身照护中的关键作用。虽然永久性回肠造口发生原发性腺癌是一种罕见并发症,但近20年报告的病例数几乎翻倍。本病例系列报告的两例患者在不到两年间隔内因该并发症先后就诊于同一医疗机构,且均长期未接受STN检查,未能识别自身造口的异常改变。
尽管原发性腺癌的确切病因尚未明确,但慢性机械性与化学性刺激、疾病易感性、腺瘤恶性转化、菌群改变以及回肠炎/倒灌性回肠炎等因素可能参与其发病过程。医疗从业者与STN在护理长期永久性回肠造口患者时应保持警惕,每次复诊时均应仔细检查造口,并建议造口患者在造口存续期间每年接受一次STN随访,以便及时发现异常増生或病变。
局限性
由于本临床病例研究采用回顾性病历审查设计,难以明确与造口护理相关的具体教育内容。但文中已提供造口装置及支撑带管理的相关信息。
致谢
感谢北阿徳莱徳地方健康网络外科专科与麻醉科临床研究护士顾问Julie Tucker博士对本文的校对与编辑。
利益冲突
作者声明无任何利益冲突。
伦理
中央阿徳莱徳地方健康网络人类研究伦理委员会(编号19710)。
资助
作者未获得本研究相关的任何资金资助
Author(s)
Kelly J Vickers
BNurs
Northern Adelaide Local Health Network
Lyell McEwin and Modbury Hospitals
Haydown Road Elizabeth Vale South Australia 5112
Email kelly.vickers@sa.gov.au
References
- Bani Hani M, Butler B, Visco J, Alttuwaybi B. Primary adenocarcinoma at ileostomy – a rare later complication: three cases and literature review. Int Surg. 2022;106:176–180.
- Morada AO, Harshavardhan Senapathi S, Bashiri A, Chai S, Cagir B. A systemic review of primary ileostomy site malignancies. Surg Endosc. 2022;36: 1750–1760.
- James SD, Hawkins AT, M’Koma AE. Adenocarcinoma at the ileostomy site after a proctocolectomy for ulcerative colitis and/or familial adenomatous polyposis: an overview. Ostomy Wound Manage. 2018;64(6):30–40. doi:10.25270/owm.2018.6.3040
- Lyon CC, Smith A. Abdominal Stomas and their Skin Disorders. 2nd ed. Informa Healthcare, UK: 2010.
- Metzger PP, Jackson Slappy AL, Chua HK, Menke DM. Adenocarcinoma developing at an ileostomy: report of a case and review of the literature. Dis Colon Rectum. 2008;51: 604–609. doi:10.1007/s10350-007-9188-x
- Procaccino L, Rehman S, Abdurakhmanov A, McWhorter P, La Gamma N, Bhaskaran MC, Maurer J, Grimaldi GM, Rilo H, Nicatro J, Coppa G, Molmenti EP, Procaccino J. Adenocarcinoma arising at ileostomy sites: Two cases and a review of the literature. World J Gastrointest Surg. 2015; 7(6):94–97. doi: 10.4240/wjgs.v7.i6.94
- Jacob M, Ponniah K, Ramanathan B, Eteuati J. Primary adenocarcinoma arising from an ileostomy site: a late complication of end ileostomies. ANZ J Surg. 2023;93: 777–778.
- Siegler L, Jedd F. Adenocarcinoma of the ileostomy occurring after colectomy for ulcerative colitis: report of a case. Dis Colon Rectum.1969;12:45–48.
- White M, Perrin A. Stoma Care Specialist Nursing: A guide for Clinical Practice. Springer:2023.
- Hammad A, Tayyem R, Milewski P, Gunasekaran S. Primary Adenocarcinoma in the ileostomy of a woman with familial adenomatous polyposis: a case report and literature review. J Med Case Rep. 2011;5:556.
- Healthdirect. Sarcoidosis. https://www.healthdirect.gov.au/sarcoidosis. Accessed 20 February 2024.
- Quah HM, Samad A, Maw A. Ileostomy carcinomas a review: the latent risk after colectomy for ulcerative colitis and familial adenomatous polyposis. Colorectal Dis. 2005;7: 538–544.
- Mosby’s Medical Dictionary. 11th Ed. Elsevier, Missouri 2022.
- Dansac Glossary. https://www.dansac.com.au/en-au/glossary
- Cressey BD, Belum VR, Scheinman P, Silvestri D, McEntee N, Livingston V, Lacouture ME, Zippin JH. Stoma care products represent a common and previously underreported source of peristomal contact dermatitis. Contact Dermatitis. 2016;76:27–33.
- Avallone MA, Kolbach-Mandel AM, Mandel IC, Mandel NS, Dietrich PN, Wessen JA, Davis CM. Polyisobutylene urolithiasis due to ileal conduit urostomy appliance: an index case. J Endourol Case Rep. 2015;1.1:41–43. doi: 10.1089/cren.2015.29016.maa
- Ananthakrishnan A, Xavier R, Podolsky D. Inflammatory Bowel Diseases: A Clinician’s Guide. Wiley Blackwell UK: 2017.
- Jensen BAH, Heyndrickx M, Jonkers D, Mackie A, Millet S, Naghibi M, Pærregaard SI, Pot B, Saulnier D, Sina C, Sterkman LGW, Abbeele PV, Venlet NV, Zoetendal EG, Ouwehand AC. Small intestine vs. colon ecology and physiology: Why it matters in probiotic administration. Cell Rep Med. 2023;4(9):101190. doi: 10.1016/j.xcrm.2023.101190
- Al-Niaimi F, Lyon CC. Primary adenocarcinoma in peristomal skin: a case study. Ostomy Wound Manage. 2010;56(1):45–47.
- Hamilton MJ, Makrauer FM, Golden K, Wang H, Friedman S, Burakoff B, Levine JS, Joshi P, Banks PA, Odze RD. Prospective evaluation of terminal ileitis in a surveillance population of ulcerative colitis patients. Inflam Bowel Dis. 2016;22(10):2448–2455.
- Iizuka T, Sawada T, Hayakawa K, Hashimoto M, Udagagwa H, Watanabe G. Successful local incision of ileostomy adenocarcinoma after colectomy for familial adenomatous polyposis: Report of a Case. Surg Today. 2002; 32:638–641.
- Toshiki M, Shu K, et al Familial adenomatous polyposis: a case report and histologic mucin study. J Clin Gastroenterol. 1999; 28:372–337.
- Suarez V, Alexander-Williams J, O’Connor HJ, Campos A, Fuggle WJ, Thompson H, et al. Carcinoma developing in ileostomies after 25 or more years. Gastroenterology. 1988;95(1):205–208.
- Chang A, Davis B, Snyder J, Pulskamp S, Nestok B, Rafferty J, Marcello P, Paquette IM. Considerations for diagnosis and management of ileostomy-related malignancy: a report of two cases. Ostomy Wound Manage. 2014;60(6):38–43.
- Schluter JE, Sinasac PA. Community stomal therapy services: a needs analysis and development of an evidence based model of care. Journal of Stomal Therapy Australia. 2020:40(1):8–13.
- Carmel JE, Colwell JC, Goldberg MT. Core Curriculum Ostomy Management. Wolters Kluwer, Philadelphia: 2016.
- Australian Commission on Safety and Quality in Health Care. Health literacy. https://www.safetyandquality.gov.au/standards/nsqhs-standards/partnering-consumers-standard/health-literacy